Cytokinetics, Incorporated (CYTK)
NASDAQ: CYTK · Real-Time Price · USD
38.00
+0.19 (0.50%)
Apr 23, 2025, 4:00 PM EDT - Market closed
Cytokinetics Revenue
In the year 2024, Cytokinetics had annual revenue of $18.47M with 145.34% growth. Cytokinetics had revenue of $16.93M in the quarter ending December 31, 2024, with 912.38% growth.
Revenue (ttm)
$18.47M
Revenue Growth
+145.34%
P/S Ratio
230.34
Revenue / Employee
$37,096
Employees
498
Market Cap
4.50B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 18.47M | 10.94M | 145.34% |
Dec 31, 2023 | 7.53M | -87.06M | -92.04% |
Dec 31, 2022 | 94.59M | 24.16M | 34.30% |
Dec 31, 2021 | 70.43M | 14.60M | 26.15% |
Dec 31, 2020 | 55.83M | 28.96M | 107.79% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
CYTK News
- 1 day ago - Cytokinetics to Announce First Quarter Results on May 6, 2025 - GlobeNewsWire
- 6 days ago - Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 23 days ago - Cytokinetics to Participate in the 24th Annual Needham Virtual Healthcare Conference - GlobeNewsWire
- 4 weeks ago - Cytokinetics Announces Launch of EARTH-HCM, a Public Health Education Tool for the Hypertrophic Cardiomyopathy Community - GlobeNewsWire
- 5 weeks ago - Cytokinetics Announces Five Presentations at the American College of Cardiology Annual Scientific Session & Expo - GlobeNewsWire
- 5 weeks ago - Cytokinetics Nears Approval: 'Buy' The New Potential Cardiology Franchise With Aficamten - Seeking Alpha
- 7 weeks ago - Cytokinetics to Participate in March Investor Conferences - GlobeNewsWire
- 7 weeks ago - Cytokinetics, Incorporated (CYTK) Q4 2024 Earnings Call Transcript - Seeking Alpha